Burosumab’s pediatric phase 2 studies in X-linked hypophosphatemia yield positive results
The data demonstrated that serum phosphorus levels, rickets, growth rates, and other functional outcomes improved with burosumab, and these treatment effects were sustained through 64 weeks of treatment.